Recent News

• 03.17.2025 - Sangamo Fourth Quarter 2024 Teleconference Call
• 03.12.2025 - Barclays 27th Annual Global Healthcare Conference
• 03.11.2025 - Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
• 03.06.2025 - Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
• 02.18.2025 - Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
• 02.06.2025 - Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
• 02.06.2025 - WORLDSymposium™ 2025
• 01.31.2025 - Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
• 01.26.2025 - FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
• 01.26.2025 - FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Recent Filings

• 02.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.06.2025 - 8-K Current report
• 01.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.24.2025 - 4 Statement of changes in beneficial ownership of securities